Clinicians have found that there is significant variation in how patients process biologic drugs – a powerful class of pharmaceuticals that treat cancer and chronic autoimmune disorders such as Crohn’s disease, rheumatoid arthritis, and multiple sclerosis. Abreos address this variation by helping clinicians deliver personalized, precision dosing tailored to the individual needs of patients. Using the Veritope platform, Abreos has cultivated a diverse portfolio of laboratory and point-of-care tests that allow for direct monitoring of blood concentrations of biologic drugs. These tests enable researchers and clinicians to know if a patient needs more of a drug to receive the therapeutic benefit or if a client’s negative side-effects are a product of excessive dosing. This not only improves patient care, but also minimizes unnecessary costs by ensuring that patients are only taking as much of these expensive drugs as they need.
We have already developed an extensive Veritope pipeline of 19 biologic drugs currently on the market and continue to develop more customized Veritopes for other biologic drugs. These Veritopes can go to market rapidly through the CLIA LDT pathway. We are also in discussions with pharmaceutical companies to co-develop and commercialize dose monitoring complementary diagnostics. Abreos has recently closed an oversubscribed $1.2 million seed round, totaling $3.5 million from grants and equity funding.